Additive Effects of Intra-arterial Tenecteplase for Successful Thrombectomy Due to Acute Basilar Artery Occlusion

China Medical University

Status and phase: Not yet enrolling; Phase 2

Conditions: Basilar Artery Occlusion; Thrombectomy; Tenecteplase

Treatments: Drug: Tenecteplase for Injection; Drug: Saline

Study type: Interventional

Funder types: Other

Identifiers

NCT05580822

ARTERIAL-TNK-BAO-202201

Details and patient eligibility

About

Recent studies revealed the safety and effectiveness of EVT in patients with acute occlusion at basilar artery, showing that up to 46% of patients receiving EVT had favorable functional outcome at 3 months (ATTENTION and BAOCHE trials, ESOC). Although the rate of successful recanalization can be as high as 90% , a large number of these patients remains to be functionally independent while recovery. In addition, a number of recent studies indicated the functional outcome of patients with successful recanalization of TICI 2b was not as good as those with TICI 3 grade. Therefore, restoring reperfusion of distal vessels and territorial microcirculation may be pivotal to further improvement of neurological outcomes for AIS patients receiving EVT. Correspondingly, a very recent Spanish multicenter randomized trial showed the effect of further functional improvement of post-EVT intra-arterial alteplase for successful mechanical thrombectomy in anterior circulation More importantly, head-to-head comparison between TNK and tPA showed the former has a significantly higher chance of reperfusion, indicating that TNK may be a potentially better candidate for post-EVT bridging.

Based on the above findings, we hypothesize in the present study that, adjunct intra-arterial tenecteplase after successful thrombectomy could enhance the functional improvement in patients with acute basilar artery occlusion.

Enrollment: 520 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 18 - 80 yro；
2. Acute symptomatic basilar artery occlusion identified by neuroimaging modalities (CTA/MRA/DSA)；
3. NIHSS ≥ 6 before thrombectomy；
4. Time from symptom onset (or last seen normal) to arterial TNK/placebo is less than 24 hours；
5. pc-ASPECTS ≥ 6 and Pons-midbrain-index ≤ 2
6. Successful recanalization（eTICI 2b-3）at the end of procedure（The maximum will be six passes or six aspirations for the patient）；Patients with an eTICI score 2b/3 on the diagnostic cerebral angiography before the onset of MT are also eligible for the study.
7. Exclusion of parenchymal hemorrhagic transformation (DynaCT/XpertCT) before intra-arterial agent administration；
8. Pre-morbid mRS ≤ 1；
9. Patient or legal proxy is able to understand and willing to provide written inform and consent.

Exclusion criteria

1. Patient received thrombolysis prior to EVT
2. NIHSS score on admission >25
3. Contraindication to IA TNK as per local national guidelines (except time to therapy)
4. Use of stents during the endovascular procedure requiring dual antiplatelet therapy during the first 24h
5. Female who is pregnant or lactating or has a positive pregnancy test at time of admission
6. Current participation in another investigation drug or device treatment study (except observational study)
7. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency
8. Known coagulopathy, INR >1.7 or use of novel anticoagulants < 48h from symptom onset
9. Platelets <100,000
10. Renal Failure as defined by a serum creatinine >3.0 mg/dl (or 265.2 μmol/l) or glomerular Filtration Rate [GFR] <30.
11. Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram for whatever reason
12. Any hemorrhage on CT/MRI
13. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal
14. Suspicion of aortic dissection
15. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol
16. History of life threatening allergy (more than rash) to TNK or contrast medium
17. SBP >185 mmHg or DBP >110 mmHg refractory to treatment
18. Serious, advanced, terminal illness with anticipated life expectancy <6 months
19. Pre-existing neurological or psychiatric disease that would confound evaluation
20. Presumed vasculitis or septic embolization
21. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas)
22. Other conditions at investigators' discretion which are not appropriate for participation.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

520 participants in 3 patient groups, including a placebo group

intra-arterial TNK infusion (0.4mg/min) via support/access catheter, over 15 minutes

Experimental group

Treatment:

Drug: Tenecteplase for Injection

intra-arterial TNK infusion (0.25mg/min) via support/access catheter, over 15 minutes

Experimental group

Treatment:

Drug: Tenecteplase for Injection

intra-arterial placebo infusion via support/access catheter, over 15 minutes

Placebo Comparator group

Treatment:

Drug: Saline